Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Familial pulmonary arterial hypertension leucopenia and atrial septal defect


Other Names for this Disease
  • Familial pulmonary arterial hypertension, leucopenia and ASD
  • Familial PAH, leucopenia and ASD
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

On this page

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Selexipag
Trade Name
(Manufacturer Name)
Uptravi
(Actelion Ltd)
Indication
The FDA has approved this product to be used in this manner.
For use of Uptravi (Selexipag) Tablets, 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg for treatment of pulmonary arterial hypertension (PAH, WHO Group I) to reduce the risks of disease progression and hospitalization for PAH.
More Information about this product Drug Information Portal

Other Names for this Disease
  • Familial pulmonary arterial hypertension, leucopenia and ASD
  • Familial PAH, leucopenia and ASD
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.